Alnylam Pharmaceuticals (United States)
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Alnylam Pharmaceuticals (United States), United States, covering academic research published from 2003 to 2024. Read More.
Open Access Percentage
55%
Total
Publications
895
Total Open
Publications
496
Total
Citations
83K
Open Access
Percentage
55%
Total
Publications
895
Total Open
Publications
496
Total
Citations
83K
Breakdown
Publisher Open
15%
Both
28%
Other Platform Open
12%
Closed
45%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 40%
150
Hybrid 26%
99
No Guarantees 34%
130
Other Platform Open
Domain 69%
244
Institution 22%
77
Other Internet 17%
59
Preprint 9%
32
Public 5%
16
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 245 |
DOI | Other Internet | 58 |
bioRxiv | Preprint | 23 |
Royal Netherlands Academy of Arts and Sciences | Institution | 22 |
Harvard University | Institution | 15 |
Figshare | Public | 15 |
medRxiv | Preprint | 9 |
Europe PMC | Domain | 9 |
King's College London | Institution | 8 |
University of Modena and Reggio Emilia | Institution | 6 |